A pH-responsive PEGylated chitosan nanocarrier was developed for the targeted delivery of 17-(Allylamino)-17-demethoxygeldanamycin (17-AAG) to HER2+ breast cancer cells. Here, ERBB2 is linked to breast carcinoma.